# Patterns of Antibiotic Use In European Hospitals




Fiona M. MacKenzie

Aberdeen Royal Infirmary, Scotland



"Development of Strategies for Control and Prevention of Antibiotic Resistance in European Hospitals"





## **ARPAC:** Antibiotic Use data

Annual, aggregated hospital data (2001)

Unit = Defined Daily Dose /100 bed-days

DDD = assumed average maintenance dose per day for a drug for its main indication in a 70kg adult

DDDs assigned by WHO collaborative Centre for Drug Statistics Methodology (Norway)

Anatomical Therapeutic Chemical (ATC) classification


J01 subclass; "antibacterials for systemic use"

	A B C	D	Е	F	G	Н	I	J	K	L	M	N
	بستنز		Grams	Nr. unit				DDD				
			per unit	doses per		ATC	Adm.	(WHO		Nr.	Nr.	Nr.
1		Name of product	dose	-	Name of antibacterial	code	route	2002)	U	packages	grams	DDD
2					Demeclocycline	J01AA01	0	0.6	g		0.0	0.0
3					Doxycyline	J01AA02	0, P	0.1	g		0.0	0.0
4					Chlortetracycline	J01AA03	0	1	q		0.0	0.0
5	S				Lymecycline	J01AA04	0, P	0.6	g		0.0	0.0
6	li				Metacycline	J01AA05	0	0.6	g		0.0	0.0
7	уc				Oxytetracycline	J01AA06	0, P	1	g		0.0	8.8
8	J01A - Tetracyclines				Tetracycline	J01AA07	0, P	1	g		0.0	0.0
9	Tet				Minocycline	J01AA08	0, P	0.2	g		0.0	0.0
10	5				Rolitetracycline	J01AA09	Р	0.35	g		0.0	0.0
11	11				Penimepicycline	J01AA10					0.0	
12	Ч Ч				Clomocycline	J01AA11	0	1	g		0.0	0.0
13					Entrance of the second statement of the second statement of the second statement of the second statement of the	J01AA20	0	0.6	g		0.0	0.0
14					Comb. of tetracyclines (other)	J01AA20						
15					Oxytetracycline, combination:	J01AA56						
16	J01B Amphe nicols				Chloramphenicol	J01BA01	0, P	3	g		0.0	0.0
17	A in a				Thiamphenicol	J01BA02	0, P	1.5	g		0.0	0.0
18					Ampicillin	J01CA01	0, P, R	2	g		0.0	0.0
19					Pivampicillin	J01CA02	0	1.05	g		0.0	0.0
20	livit				Amoxicillin	J01CA04	0, P	1	g		0.0	0.0
21	act				Bacampicillin	J01CA06	0	1.2	g		0.0	0.0
22					Epicillin	J01CA07	0, P	2	g		0.0	0.0
23	spectrum				Pivmecillinam	J01CA08	0	0.6	g		0.0	0.0
24	spe				Mecillinam	J01CA11	Р	1.2	g		8.8	0.0
25	ed				Metampicillin	J01CA14	0, P	1.5	g		0.0	0.0
26	end ti-p				Talampicillin	J01CA15	0	2	g		8.8	0.0
-	3 5				T	104/04/17	-	-			00	15 15

ABC Calc


Monnet DL. ABC Calc - Antibiotic consumption calculator [Microsoft® Excel application]. Version 3.0 Copenhagen (Denmark): Statens Serum Institut 2005


	9   C	D	E	F		G	Н	I	J
					Nr. beds	453	4		
				Occupancy inde	(during study period)	0.86			
					rs (during study period)	365		<u> </u>	
					OR			0	P
					Nr. bed-days	142196.7			
					Nr. Deu-uays	142190.7			
A	ntibacte	erials	for sy	/stemic use, by A	TC level				
				, <b>,</b>					
			n a anti-	and the sector of the state of the				Nr.	U- 000
ATC	C ATC	ATC		al level of subdivision		Nr.		grams per 100	Nr. DDD per 100
leve		level 4		issification system)	Excl. colistin (in MU)	grams	Nr. DDD	bed-days	bed-days
J01	0tib.a								
JUI		otorio /	a far an	tamia una <i>la</i> uarall\		450000 4	445247.0	405.7	04 A
				stemic use (overall)		150366.4	115317.9	105.7	81.1 0 9
		- Tetra	cycline	S		150366.4 137.3	115317.9 1267.0	105.7 0.1	81.1 0.9
		- Tetra - Ampl	icycline henicol	s S	rilling	137.3 0.0	1267.0 0.0	0.1 0.0	81.1 0.9 0.0
		- Tetra - Ampl - Beta-	cycline henicol lactam	es s antibacterials, Penie		137.3 0.0 103082.4	1267.0 0.0 66177.3	0.1 0.0 72.5	0.9 0.0 46.5
		- Tetra - Ampl - Beta-	icycline henicol: -lactam - Penicillir	s s antibacterials, Penio ns with extended spectrum	(PES)	137.3 0.0 103082.4 14362.0	1267.0 0.0 66177.3 10147.8	0.1 0.0 72.5 10.1	81.1 0.9 0.0 46.5 7.1 7.0
		- Tetra - Ampl - Beta-	icycline henicol -lactam - Penicillir PES wit	es s antibacterials, Penions with extended spectrum hout anti-pseudomonal act	(PES) ivity	137.3 0.0 103082.4 14362.0 10746.0	1267.0 0.0 66177.3 10147.8 9889.5	0.1 0.0 72.5 10.1 7.6	0.9 0.0 46.5 7.1 7.0
		- Tetra - Ampl - Beta JO1CA	icycline henicol: - Iactam - Penicillir - PES wit - PES wit	s s antibacterials, Penio ns with extended spectrum hout anti-pseudomonal activity h anti-pseudomonal activity	(PES) ivity V	137.3 0.0 103082.4 14362.0 10746.0 3616.0	1267.0 0.0 66177.3 10147.8 9889.5 258.3	0.1 0.0 72.5 10.1	0.9 0.0 46.5 7.1 7.0 0.2
		- Tetra - Ampl - Beta JO1CA	icycline henicol - Penicillir <i>PES wit</i> - Beta-lac	es s antibacterials, Penions with extended spectrum hout anti-pseudomonal act h anti-pseudomonal activity tamase sensitive penicilling	(PES) ivity Y	137.3 0.0 103082.4 14362.0 10746.0	1267.0 0.0 66177.3 10147.8 9889.5	0.1 0.0 72.5 10.1 7.6 2.5	0.9 0.0 46.5 7.1 7.0
		- Tetra - Ampl - Beta JO1CA JO1CE JO1CE	icycline henicol: - Penicillir - PES wit - Beta-lac - Beta-lac	s s antibacterials, Penio ns with extended spectrum hout anti-pseudomonal activity h anti-pseudomonal activity	(PES) ivity Y	137.3 0.0 103082.4 14362.0 10746.0 3616.0 796.4	1267.0 0.0 66177.3 10147.8 9889.5 258.3 272.8	0.1 0.0 72.5 10.1 7.6 2.5 0.6	0.9 0.0 46.5 7.1 7.0 0.2 0.2
		- Tetra - Ampl JO1CA JO1CE JO1CE JO1CF	icycline henicol: - Penicillir PES wit - Beta-lac - Beta-lac - Beta-lac	s antibacterials, Penio s with extended spectrum hout anti-pseudomonal act h anti-pseudomonal activity tamase sensitive penicillins tamase resistant penicillins	(PES) ivity Y	137.3 0.0 103082.4 14362.0 10746.0 3616.0 796.4 5136.6	1267.0 0.0 66177.3 10147.8 9889.5 258.3 272.8 2568.3	0.1 0.0 72.5 10.1 7.6 2.5 0.6 3.6	0.9 0.0 46.5 7.1 7.0 0.2 0.2 0.2 1.8
		- Tetra - Ampl JO1CA JO1CE JO1CE JO1CF	icycline henicol: - Penicillir <i>PES wit</i> - Beta-lac - Beta-lac - Beta-lac - Beta-lac	s s antibacterials, Peni ns with extended spectrum <i>hout anti-pseudomonal activit</i> <i>h anti-pseudomonal activit</i> tamase sensitive penicillins tamase resistant penicillins ctamase inhibitors	(PES) ivity y mase inhibitors, BLI)	137.3 0.0 103082.4 14362.0 10746.0 3616.0 796.4 5136.6 0.0	1267.0 0.0 66177.3 10147.8 9889.5 258.3 272.8 2568.3 0.0	0.1 0.0 72.5 10.1 7.6 2.5 0.6 3.6 0.0	0.9 0.0 46.5 7.1 7.0 0.2 0.2 1.8 0.0
		- Tetra - Ampl JO1CA JO1CE JO1CE JO1CF	icycline henicol: - Penicillir <i>PES wit</i> - Beta-lac - Beta-lac - Beta-lac - Comb. o <i>PES wit</i>	s antibacterials, Penio hs with extended spectrum hout anti-pseudomonal act h anti-pseudomonal activity tamase sensitive penicillins tamase resistant penicillins ctamase inhibitors of penicillins (incl. beta-lacts	(PES) ivity y mase inhibitors, BLI) ivity + <i>BLI</i>	137.3 0.0 103082.4 14362.0 10746.0 3616.0 796.4 5136.6 0.0 82787.5	1267.0 0.0 66177.3 10147.8 9889.5 258.3 272.8 2568.3 0.0 53188.4	0.1 0.0 72.5 10.1 7.6 2.5 0.6 3.6 0.0 58.2	0.9 0.0 46.5 7.1 7.0 0.2 0.2 1.8 0.0
		- Tetra - Ampl JO1CA JO1CE JO1CE JO1CF	icycline henicol: - Penicillir PES wit - Beta-lac - Beta-lac - Beta-lac - Comb. o PES wit PES wit	s antibacterials, Peni of with extended spectrum hout anti-pseudomonal activity tamase sensitive penicillins tamase resistant penicillins tamase inhibitors of penicillins (incl. beta-lacta hout anti-pseudomonal activity	(PES) ivity y mase inhibitors, BLI) ivity + <i>BLI</i>	137.3 0.0 103082.4 14362.0 <b>10746.0</b> <b>3616.0</b> 796.4 5136.6 0.0 82787.5 <b>50911.5</b>	1267.0 0.0 66177.3 10147.8 9889.5 258.3 272.8 2568.3 0.0 53188.4 50911.5	0.1 0.0 72.5 10.1 7.6 2.5 0.6 3.6 0.0 58.2 35.8	0.9 0.0 46.5 7.1 7.0 0.2 0.2 1.8 0.0
	J01A J01B J01C	- Tetra - Ampl JO1CA JO1CE JO1CF JO1CG JO1CR	icycline henicol: - Penicillir PES wit - Beta-lac - Beta-lac - Beta-lac - Comb. o PES wit PES wit Other cu	s antibacterials, Penio hs with extended spectrum <i>hout anti-pseudomonal activity</i> tamase sensitive penicillins tamase resistant penicillins ctamase inhibitors of penicillins (incl. beta-lacts <i>hout anti-pseudomonal activity</i>	(PES) ivity y mase inhibitors, BLI) ivity + <i>BLI</i>	137.3 0.0 103082.4 14362.0 10746.0 3616.0 796.4 5136.6 0.0 82787.5 50911.5 31876.0	1267.0 0.0 66177.3 10147.8 9889.5 258.3 272.8 2568.3 0.0 53188.4 50911.5 2276.9	0.1 0.0 72.5 10.1 7.6 2.5 0.6 3.6 0.0 58.2 35.8 22.4	0.9 0.0 46.5 7.1 7.0 0.2 0.2 1.8 0.0 37.4 35.8 1.6
	J01A J01B J01C	- Tetra - Ampl JO1CA JO1CE JO1CF JO1CG JO1CR	icycline henicol: - Penicillir PES wit: - Beta-lac - Beta-lac - Beta-lac - Comb. o PES wit: Other ci r beta-l:	S antibacterials, Peni of with extended spectrum hout anti-pseudomonal activity tamase sensitive penicillins tamase resistant penicillins tamase inhibitors of penicillins (incl. beta-lacta hout anti-pseudomonal activity ombinations of penicillins	(PES) ivity mase inhibitors, BLI) ivity + BLI y + BLI	137.3 0.0 103082.4 14362.0 10746.0 3616.0 796.4 5136.6 0.0 82787.5 50911.5 31876.0	1267.0 0.0 66177.3 10147.8 9889.5 258.3 272.8 2568.3 0.0 53188.4 50911.5 2276.9 0.0	0.1 0.0 72.5 10.1 7.6 2.5 0.6 3.6 0.0 58.2 35.8 22.4 0.0	0.9 0.0 46.5 7.1 7.0 0.2 0.2 1.8 0.0 37.4 35.8 1.6




# Total Antibiotic Consumption

### Antibiotic use data: Distribution (n = 140) 2001






### Median total antibiotic use: 2001 By Geographical Region, n = 140 p < 0.001





# Antibiotic Consumption: The major classes




### Median use of penicillin class (J01 C) By Geographical Region, n = 140

p < 0.001






### Median use of non-penicillin beta lactams (J01 D) By Geographical Region, n = 140




### Non-penicillin B-lactams


#### J01 D sub-classes – as proportion of total J01 D use



# Antibiotic Consumption: Individual antibiotics

### Relationship between number of individual antibiotics used and total antibiotic use





### **Top - 5 antibiotics used**

All hospitals, n = 140

### WEST, n = 52



1	Amox + BLI	Р
2	Amox + BLI	Ο
3	Ciprofloxacin	Ο
4	Cefuroxime	Р
5	Amoxicillin	Ο

### **Top - 10 antibiotics used** (Median values. % of total use) France

1	Amox + BLI	Ο	27%
2	Amoxicillin	0	16%
3	Ofloxacin	0	5%
4	Amoxicillin	Ρ	5%
5	Amox + BLI	Ρ	4%
6	Ceftriaxone	Ρ	3%
7	Ciprofloxacin	0	2%
8	Pristinamycin	0	2%
9	Ciprofloxacin	Ρ	2%
10	Sulfa - Trim	Ο	1%


67 agents used Top-10 = 67% of total use

## Recommendations Hospitals

- Agree universal unit
- Local surveillance of antibiotic use
- Feedback to prescribers
- Investigate fluctuations & relationship with resistance
- Clinical pharmacy services to support prescribing

# Recommendations National / European Health Authorities

- National programmes to monitoring antibiotic use.
- Implementation of a national surveillance system for collation, feedback and benchmarking of antibiotic consumption data in hospitals.
- Integrate with National programmes co-ordinating antibiotic resistance, antibiotic stewardship, policy and practice.
- Education.




ARPAC participating hospitals ARPAC Steering Group Benjamin Pelle European Commission ESCMID (ESGAP)


www.abdn.ac.uk/arpac

# Antibiotic Consumption and

## Antibiotic resistance



#### Relationship between MRSA prevalence and antibiotic use Spearman Rank Correlation Coefficients



Antibiotic use (DDDs / 100 occupied bed days

## ARPAC European hospitals (n=263)

- <u>140</u> ARPAC hospitals submitted useable antibiotic consumption data
- Project ICARE <u>n=45</u> (Intensive Care Antimicrobial Resistance Epidemiology)
- CDC / NNIS system <u>n=68</u> (National Nosocomial Infections Surveillance)
- SCOPE <u>n=37</u>

(Surveillance and Control of Pathogens of Epidemiological Importance)

### **Exploration of variation in Antibiotic Use**

Geographical region Expenditure on health as % of GDP EU status

Hospital size Teaching status

ICU size ICU beds as proportion of total

Number of paediatric beds Paediatric beds as proportion of total

Number of long stay beds Long stay beds as proportion of total











### Antibiotic use data: Distribution (n = 140) 2005



# Usage of antibiotics ranked 1-10, expressed as % of total usage

(n = 140)



## **Top - 5 antibiotics used**

### Central / Eastern Europe, n = 34

### South East Europe, n = 8





## **Top - 5 antibiotics used**

### Northern Europe, n = 19

### Southern Europe, n = 26



1	Amox + BLI	0	
2	Amox + BLI	Р	
3	Ciprofloxacin	Ο	
4	Ceftriaxone	Ρ	
5	Cefuroxime	Ο	

# European differences in numbers of antibiotics prescribed (formulary)

